Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine to reduce endothelial P-selectin expression in pediatric sickle cell disease
2021-001351-13Phase 4Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of famotidine in sickle cell disease (SCD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in plasma soluble P-selectin concentration. Started Sep 2021; status: active.
02
Drugs
famotidine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2021-001351-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001351-13.